These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

599 related items for PubMed ID: 30821591

  • 21. Are antihistamines still used during omalizumab treatment for chronic spontaneous urticaria?
    Melé-Ninot G, Serra-Baldrich E, Spertino J, Guilarte M, Ribó González P, Lleonart-Bellfill R, Figueras-Nart I, Bonfill-Ortí M, Depreux N, Sala-Cunill A, Bielsa-Marsol I, Baliu-Piqué C, Sanmartín-Novell V, Garcia-Navarro X, Expósito-Serrano V, Garnica-Velandia D, Diaz-Sarrió MC, Gómez-Armayones S, Gich Saladich I, Giménez-Arnau A.
    Eur J Dermatol; 2022 Sep 01; 32(5):629-631. PubMed ID: 36468733
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Analysis of clinical factors as possible predictors of response to omalizumab and relapse after treatment discontinuation in chronic spontaneous urticaria.
    Foti C, Romita P, Ambrogio F, Fanelli M, Panebianco R, Vena GA, Cassano N, Ragusa M, Giuffrida R, Papaianni V, Borgia F, Cannavò SP, Guarneri F.
    Dermatol Ther; 2022 Feb 01; 35(2):e15248. PubMed ID: 34877757
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Omalizumab in Chronic Spontaneous Urticaria: A Brazilian Real-Life Experience.
    Ensina LF, Valle SO, Juliani AP, Galeane M, Vieira dos Santos R, Arruda LK, Melo JM, de Souza PK, Serpa FS, de Andrade DM, França AT, Campos RA, Camelo-Nunes I, Solé D.
    Int Arch Allergy Immunol; 2016 Feb 01; 169(2):121-4. PubMed ID: 27055122
    [Abstract] [Full Text] [Related]

  • 26. Hematologic parameters as biomarkers for antihistamine and omalizumab resistance in chronic spontaneous urticaria.
    Magen E, Waitman DA, Kahan NR.
    Allergy Asthma Proc; 2021 Jan 01; 42(1):e17-e24. PubMed ID: 33404397
    [Abstract] [Full Text] [Related]

  • 27. Omalizumab in Chronic Spontaneous Urticaria (CSU): Real-Life Experience in Dose/Interval Adjustments and Treatment Discontinuation.
    Brás R, Costa C, Limão R, Caldeira LE, Paulino M, Pedro E.
    J Allergy Clin Immunol Pract; 2023 Aug 01; 11(8):2392-2402. PubMed ID: 36720390
    [Abstract] [Full Text] [Related]

  • 28. Effectiveness and safety of Omalizumab in the treatment of chronic spontaneous urticaria: Systematic review and meta-analysis.
    Rubini NPM, Ensina LFC, Silva EMK, Sano F, Solé D.
    Allergol Immunopathol (Madr); 2019 Aug 01; 47(6):515-522. PubMed ID: 31607407
    [Abstract] [Full Text] [Related]

  • 29. Addition of omalizumab to antihistamine treatment in chronic urticaria: A real-world study in China.
    Chen YD, Maurer M, Yu M, Tu P, Zhao ZT.
    Ann Allergy Asthma Immunol; 2020 Aug 01; 125(2):217-219. PubMed ID: 32371240
    [No Abstract] [Full Text] [Related]

  • 30. Real-life, long-term data on efficacy, safety, response and discontinuation patterns of omalizumab in a Greek population with chronic spontaneous urticaria.
    Apalla Z, Sidiropoulos T, Kampouropoulou E, Papageorgiou M, Lallas A, Lazaridou E, Smaragdi M, Delli F.
    Eur J Dermatol; 2020 Dec 01; 30(6):716-722. PubMed ID: 33258453
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Improvement of patient outcomes following therapeutic optimization of chronic urticaria: two-year data from France as part of the international real-life AWARE study.
    Giordano-Labadie F, Becherel PA, Pralong P, Outtas O, Ruer-Mulard M, Berard F, Greco M, Lacour JP, Debons-Peyroutet M, Pelvet B, Lamirand A, Guillet G.
    Eur J Dermatol; 2021 Apr 01; 31(2):217-224. PubMed ID: 34001470
    [Abstract] [Full Text] [Related]

  • 34. Omalizumab for chronic spontaneous urticaria in "complex" patients: data from real-life clinical practice.
    Vollono L, Piccolo A, Lanna C, Esposito M, Bavetta M, Campione E, Bianchi L, Diluvio L.
    Drug Des Devel Ther; 2019 Apr 01; 13():3181-3186. PubMed ID: 31564834
    [Abstract] [Full Text] [Related]

  • 35. Comparison between chronic spontaneous urticaria and chronic induced urticaria on the efficacy of omalizumab treatment: A systematic review and meta-analysis.
    He ZH, Qiu SC, Huang ZW, Zhang GQ, An QQ, Qu F, Wang N.
    Dermatol Ther; 2022 Dec 01; 35(12):e15928. PubMed ID: 36222320
    [Abstract] [Full Text] [Related]

  • 36. Effect of omalizumab on angioedema in H1 -antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial.
    Staubach P, Metz M, Chapman-Rothe N, Sieder C, Bräutigam M, Canvin J, Maurer M.
    Allergy; 2016 Aug 01; 71(8):1135-44. PubMed ID: 27010957
    [Abstract] [Full Text] [Related]

  • 37. It is never too late to treat chronic spontaneous urticaria with omalizumab: Real-life data from a multicenter observational study focusing on elderly patients.
    Martina E, Damiani G, Grieco T, Foti C, Pigatto PDM, Offidani A.
    Dermatol Ther; 2021 Mar 01; 34(2):e14841. PubMed ID: 33527659
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Therapeutic Strategy According to Differences in Response to Omalizumab in Patients With Chronic Spontaneous Urticaria.
    Giménez Arnau AM, Valero Santiago A, Bartra Tomás J, Jáuregui Presa I, Labrador Horrillo M, Miquel Miquel FJ, Ortiz de Frutos J, Sastre J, Silvestre Salvador JF, Ferrer Puga M.
    J Investig Allergol Clin Immunol; 2019 Mar 01; 29(5):338-348. PubMed ID: 30222111
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 30.